Regeneron Pharmaceuticals is a biotechnology company founded in 1988 that invents, develops and commercializes medicines for serious diseases. The company operates a global network with over 15,000 employees, including more than 1,400 with MDs or PhDs. Since its founding, Regeneron has spent over 35 years conducting research and development, with nearly all its approved treatments and product candidates developed internally in company laboratories.
The company's technical capabilities span antibody discovery and engineering, bispecific antibodies, and genetic medicine platforms. VelociSuite® is its proprietary antibody discovery technology that produces fully human antibodies and new classes of bispecific antibodies. The Regeneron Genetics Center® provides data-powered insights for genetic research to support the discovery and development of new medicines. Regeneron's pipeline addresses eye diseases, allergic and inflammatory conditions, cancer, cardiovascular diseases, metabolic diseases, neurological disorders, hematologic conditions, infectious diseases, and rare diseases.
The company was founded and is led by physician-scientists, with a stated focus on translating science into clinical medicine. Its emphasis on proprietary technologies, data-driven discovery, and internally developed products reflects a research-intensive approach to drug development and commercialization.
